Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an update.
Shanghai Fosun Pharmaceutical announced the resignation of Mr. Wu Yifang as a non-executive director due to personal work reassignment, effective September 30, 2025. The company proposed the appointment of Mr. Liu Yi as an executive director, subject to shareholder approval. Mr. Liu, currently the CEO and president of the company, has extensive experience in medical devices and diagnostics, and holds several leadership roles within the company and its subsidiaries.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, focusing on the pharmaceutical and healthcare industry. It operates through various subsidiaries, providing medical devices, diagnostics, and biotech solutions, and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 11,635,533
Technical Sentiment Signal: Buy
Current Market Cap: HK$81.13B
For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.